Pinned Tweet
$INOā¦
BioPulse retweeted
$LXEO large unmet need here ir.lexeotx.com/static-files/ā¦
$LXEO Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and 44% mean reduction in premature ventricular contractions at latest assessment
LX2020 generally well tolerated across 10 participants with no clinically significant complement activation
U.S. Food and Drug Administration open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020
Cash, cash equivalents and investments of $219.1 million expected to provide operational runway into 2028
Company to host webcast today at 8:00 AM ET
$AQST green on another red day. Insider buys, curl and PDUFA - A+. Should make a move..
BioPulse retweeted
$AQST - Anaphylm will probably be approved before the PDUFA date of March 16, 2027. I believe Anaphylm will be approved before the biggest allergy conference of the year. Itās the AAAAI annual meeting on February 19-22, 2027. This would potentially be āthe coming out party for Anaphylmā as Sherry Korczynski-Chief Commercial Officer puts it.
ARS Pharmaceuticals got approval 142 days after resubmitting the NDA for Neffy. If this holds true or close enough then Anaphylm should be approved around the second week of February (7-12). That is 1 week prior to Quad AI (AAAAI) annual meeting.
If Approved, Anaphylm will be the biggest event at the meeting.
annualmeeting.aaaai.org/atteā¦
BioPulse retweeted
This is such a fucking disgrace. Insider trading of a grand scale.
Just A Coincidence? Both Trump And Ro Khanna Sold Nvidia Stock Before CEO Scandal Erupted zerohedge.com/political/justā¦
BioPulse retweeted
$SVRA
-HC Wainwright initiates Savara coverage at Buy
-Highlights MOLBREEVI, a once-daily inhaled granulocyte-macrophage colony-stimulating factor, that could become the first FDA-approved therapy for autoimmune pulmonary alveolar proteinosis
-Sets $10 target
investing.com/news/analyst-rā¦
Insider buys and another one waiting to pop - $AQST.
$AQST - Will be in double digits.
I had lunch with on Tuesday with a manager of a large medical clinic. She said she gets severe hives when she accidentally eats shellfish. I asked if she was prescribed a rescue epinephrine and she said yes but the EpiPen is at home. She said theyāre too bulky to carry with her. I said thereās another epinephrine on the market thatās a nasal spray called Neffy. She didnāt know. I said no injections. She said nice! I will look into getting that. I said but you still have to remember to carry the two nasal sprays with you. Itās less bulky than EpiPen.
Then I said or you can wait for another option. Itās called Anaphylm. Itās waiting to be approved by the FDA. Itās a film that you put under your tongue. You donāt even have to swallow. Epinephrine is absorbed by sublingual tissue (under the tongue) rather than being swallowed into the digestive tract. It works faster than other options on the market right now. Best of all, it can be carried on the back of your phone.
She said, āReally?! Thatās awesome! I will wait for that one!ā
I have had similar conversations with doctors, PAs, NPs, and I get the same in awe responses when it comes to which option they would prescribe for their patients. Two years ago I said SPRY is in a tough situation. They have worked so hard to get a Neffy approved only to see Anaphylm coming to the market soon after. I am telling you right now, Anaphylm will put ARS out of business. Anaphylm is too good. Aquestive conducted a survey among patients, healthcare providers and caregivers. They overwhelmingly chose Anaphylm. Itās not even close.
Donāt take my word for it. Ask yourself the same question. Based on the convenient features and the efficacy of Anaphylm, would you even think about another option if itās for yourself or someone you care about?
The choice is Anaphylm, and itās an easy one.
Held up on an otherwise horrible day. Took a quick gain. One to watch for a continuation if XBI stabilizes. $BLTE
315
BioPulse retweeted
HC Wainwright & Co. assumes coverage of Savara at Buy, sets price target at $10
$SVRA
BioPulse retweeted
$PFE dropped Metsera alleged oral GLP1. Also dropped GIP peptide ..
Now no talk about single amylin trial data.
Amylin and GLP1 data ā just for PK and safety ā
Essentially the Metsera platform that Pfizer M&A head Andrew Baun talked about trickled to one semaglutide efficacy GLP1. That might be given monthly .. we donāt know how popular any monthly will be given irreversibility of clinical effects .. bad or good.
And how much Pfizer will generate from 12 shorts per year ?
$AMGN has its issues with monthly MariTide not the least is viscous 2.5 ML solution that pt has to inject.
After all obesity not as crowded as $JNJ CEO believes ?
Waw ā¦since when $PFE needs help for funding its clinical trials. ? And giving out some milestones and loyalties š
Why not cutting the dividend?
Bourla likely does not have confidence in this GLP1 asset ?
You do not compete in the biggest market against the trillion $ leader $LLY with a subpar asset that is barely competitive with $NVO sema ?
Trying to save a few billions on acquisition.. and then u get stuck with billions in trials cost..
BioPulse retweeted
Replying to @Biotechnerd1
$SVRA if you look at it
No treatment available. Monopoly
No safety issues compared to placebo
Excellent data Ph3 (maybe 1 lesser secondary)
PDUFA pushed forward, not rejected
Orphan status
If ā
by FDA, EU UK follow
Commercial USA by Q1 '27
SOC instantly
BioPulse retweeted
$PRAX
Raymond James is very bullish- 945 PT.
Raymond James reiterated $PRAX Strong Buy-$945 and said--We continue to view Praxis as one of the most compelling setups in SMID biotech, with the next few months offering multiple opportunities to unlock the value of what we believe could become two multi-billion-dollar CNS franchises.
[DRUG JAZZ RAPP SAGE UCBJY ESAIY OVID XENE]
Our deep dive (link) into relu's mechanism, breadth of preclinical evidence, and EMERALD's heterogeneity risk leaves us constructive on both the probability of Ph3 success and the magnitude of its commercial opportunity.
Separately, our due diligence (link) on ulixa's clinical and regulatory package, including its statistical considerations and regulatory precedent, underpins our high conviction in approval at the January 29 PDUFA.
We are encouraged by management's commercial readiness, with relu's commercial organization fully hired and ulixa's field-force buildout progressing ahead of potential launches.
Taken together, we believe Praxis is approaching a transformational stretch, with a catalyst-rich outlook, substantial commercial upside, and a balance sheet that positions the company to execute from a position of strength.
BioPulse retweeted
Chop chop BP , no time to waste
My take on BP moves:
$jnj : $cogt , $dftx , $ptgx
$lly: $abvx , $mane , $celc , $prax
$mrk: $lqda, $rvmd
$sny: $pcvx , $insm
$abbv: $xene , $prax , $abvx , $vktx
$azn: $cgon , $rytm, $insm, $abvx
$nvs: $cytk , $srrk , $vrdn
$Rhhby: $iron , $vera, $cccc
$pfe: $celc , $cogt , $arct
$bms: $elvn , $cldx
$gsk: $cldx, $amlx , $cccc
$nvo: $gpcr, $ewtx , $rytm
BioPulse retweeted
$INOā¦






















